Afuco™ Anti-Human INSR ADCC Therapeutic Antibody (AGT-182), ADCC Enhanced
Anti-INSR ADCC Enhanced Antibody (AGT-182) is an ADCC enhanced antibody produced by our Afuco™ platform. AGT‑182 is an investigational enzyme replacement therapy (ERT) for the treatment of neurological complications in patients with Hunter syndrome. Currently approved treatments for Hunter syndrome do not penetrate the BBB and therefore do not address the severe and progressive neurological complications of the disease. AGT-182 is a fusion protein of iduronate-2-sulfatase (IDS), engineered to cross the BBB by binding to insulin receptors located on the BBB. AGT‑182 crosses the BBB safely at unprecedented levels.
| Supplier | Creative Biolabs |
|---|---|
| Product # | AFC-423CL |
| Pricing | Inquiry |
| Host | Human |
| Target | INSR |
| Species Reactivity | Human |
| Type | ADCC enhanced antibody |
| Storage | Store at 4°C for up to 3 months. For longer term storage aliquot into small volumes and store at -20°C. |